Tuesday, September 8, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
News

Apple acquires neural-sensor startup Sonera Magnetics

Apple's acquisition of Berkeley-based magnetic-sensor startup Sonera Magnetics, closed in May 2026 and disclosed publicly on 8 September 2026 via the European Commission's Digital Markets Act acquisitions database, is the company's first move from hosting third-party brain-computer interface signals to owning proprietary neural-sensor IP. Sonera builds solid-state acoustically-driven ferromagnetic resonance (ADFMR) magnetometers, a room-temperature alternative to SQUID-based magnetoencephalography (MEG). The company raised US$11 million in seed financing in September 2023 from a lead-heavy syndicate including Founders Fund, Benchmark, Amplify Partners, IVP, Craft Ventures, and 8VC. Deal terms were not disclosed. Sonera's website was taken offline post-acquisition. Apple's prior BCI-adjacent moves were the AirPods ear-canal biosignal patent (filed January 2023), the BCI HID accessibility protocol for iOS 26, iPadOS 26 and visionOS 26 launched with Synchron on 13 May 2025, and hosting of Cognixion's non-invasive EEG clinical trial on Vision Pro from October 2025. Owning Sonera's magnetic-sensor IP puts Apple directly against Meta's Neural Band (surface EMG) and the non-surgical BCI operator field (Merge Labs ultrasound, Subsense nanoparticle, Neurable EEG earbuds).

Sep 9, 2026 · 6 min read

Policy & Regulation

Four senior BCI neurosurgeon-scientists use Nature Neuroscience to press for tighter research ethics as implant numbers scale

Four clinician-scientists from Mayo Clinic, University College London, and Sichuan University published a Comment in Nature Neuroscience on 7 September 2026 setting out four ethical priorities for implantable brain-computer interface research: separating research participation from patient care, ensuring long-term support for study participants, avoiding disproportionate risks to participants for benefits realised mainly by others, and grounding research in meaningful clinical purpose. Lead author Kai J. Miller (Mayo Clinic) is the corresponding author. Senior author Gerwin Schalk (West China Hospital, Sichuan University) is the second corresponding author. Co-author Harith Akram (UCL Queen Square) declares a conflict of interest as Chief Investigator of Neuralink's GB-PRIME UK study. The Comment lands one day after Germany's outgoing federal data protection commissioner pressed Europe for tighter rules on bidirectional BCI, and ten months after UNESCO's General Conference adopted the first global standard on the ethics of neurotechnology in November 2025.

Sep 8 · 6 min read

Policy & Regulation

Germany's data protection commissioner presses Europe for tighter rules on bidirectional brain-computer interfaces

Prof. Dr. Louisa Specht-Riemenschneider, the outgoing German Federal Data Protection and Freedom of Information Commissioner (BfDI), used a BCI-themed academic conference at the University of Bonn on 4 September 2026 to press for tighter European handling of neural data. Her formal underpinning is a Berlin Group Working Paper on Emerging Neurotechnologies published on 15 May 2025 through BfDI, which invokes GDPR Article 9 (health and biometric data) and the EU AI Act (Article 5 subliminal-manipulation ban, Annex III high-risk classification for medical BCI) as existing legal ground. The intervention lands one month before Specht-Riemenschneider steps down for health reasons on 30 September 2026. Her Bundestag-elected successor Prof. Dr. Moritz Hennemann of Freiburg takes office on 1 October 2026, and his own position on neurodata is not publicly disclosed.

Sep 6 · 6 min read

Industry News

Ray Kurzweil joins nanoparticle-BCI startup Subsense as Product and Vision Advisor

Ray Kurzweil, the futurist and inventor who has argued for two decades that brain-computer interfaces will arrive through molecular-scale machines rather than through skull-drilled implants, has joined Palo Alto-based Subsense as Product and Vision Advisor. Subsense unveiled the appointment on the evening of 2 September 2026 at its Palo Alto headquarters. Subsense, founded 2022 by CEO Tetiana Aleksandrova and Artem Sokolov, is developing a non-surgical BCI based on intranasally-delivered nanoparticles paired with a wearable magnetic-coil headset. The company has raised US$27 million in seed financing led by Sokolov's Golden Falcon Capital and remains in preclinical mouse-model work. The appointment lands one week after Merge Labs and Butterfly Network's chip-supply deal established the ultrasound-BCI industrial base, and adds a molecular modality to the non-surgical BCI landscape.

Sep 4 · 5 min read

Market Moves

NMPA clears Tiankai Suishi's non-invasive EEG cap for cognitive-impairment diagnosis

China's National Medical Products Administration approved a non-invasive EEG-cap diagnostic device made by Tianjin-based Tiankai Suishi Intelligent Technology on 19 August 2026 for assessing cognitive impairment. The device sits in the diagnostic tier of China's growing brain-computer interface pipeline: Class II non-invasive rather than the Class III invasive category cleared by Neuracle in March 2026. Tiankai Suishi is a Tianjin University-linked startup founded 2023, led by Gu Bin, with a depression-diagnosis product also filed with NMPA. The approval extends China's Industrial Builder posture from a single invasive-BCI flagship into diagnostic-device territory anchored on the country's ageing-population indications: Alzheimer's, schizophrenia-linked cognitive dysfunction, and depression.

Sep 3 · 4 min read

Industry News

Merge Labs picks Butterfly's ultrasound-on-chip for its brain-computer interface build

Merge Labs, the US$252 million OpenAI-backed neural interface startup, has selected Butterfly Network (NYSE:BFLY) as its exclusive ultrasound-on-chip supplier under a multi-year Butterfly Embedded licensing deal announced 1 September 2026. The agreement covers Butterfly's Poseidon Family of Ultrasound-on-Chip for Merge's neural interface development, with upfront payments, milestones, hardware purchase commitments, technology access fees, and future royalties. Financial figures were not disclosed. Butterfly retains the right to license the same technology to other companies in the field. Ultrasound BCI now has a US-listed industrial supply chain.

Sep 1 · 4 min read

Industry News

CorTec wins a second FDA Breakthrough Device Designation for its Brain Interchange implant, this one for communication

German BCI operator CorTec GmbH announced on 31 August 2026 that FDA has granted a second Breakthrough Device Designation for its Brain Interchange implant, covering computer cursor control for people with non-progressive quadriplegia. The company's first Breakthrough Designation, in April 2026, covered stroke motor rehabilitation. Both designations apply to the same fully implantable, wireless, battery-free, bidirectional closed-loop platform with non-penetrating cortical surface electrodes. CorTec is now running two parallel FDA regulatory processes on identical hardware. The European regulatory route (EMA, CE Mark) is absent from the announcement.

Sep 1 · 5 min read

Market Moves

Cortical Labs names co-founder Brett Kagan as CEO

Melbourne-based Cortical Labs, the synthetic biological intelligence company behind the CL1 biological computer and the 2022 DishBrain neuron-on-chip study, appointed co-founder Brett Kagan as Chief Executive Officer on 28 August 2026, effective immediately. Kagan was previously Chief Scientific Officer and Chief Operating Officer. Co-founder Hon Weng Chong steps down as CEO after seven years. Long-time investor Radar Ventures spoke publicly for the investor base. Cortical Labs is not a brain-computer interface operator; the CL1 platform runs computation on lab-grown human neurons rather than reading signals from an implanted human brain. InsideBCI covers this as adjacent-category leadership news.

Sep 1 · 6 min read

Policy & Regulation

India's DPDPA treats brain signals like a shopping cart, a legal scholar argues

In a LiveLaw analysis published 30 August 2026, CHRIST University Assistant Professor Namit Srivastava argues that India's Digital Personal Data Protection Act 2023 applies the same consent framework to neural data as it applies to a shopping cart, and that MeitY should add neural data as a sensitive category via delegated rule-making under Section 40 without reopening the Act. The piece is legal-scholar analysis, not Indian government policy. It lands two days after the 28 August ADI Neuroscience US$1 billion India neurotech fund announcement.

Aug 30 · 5 min read